2026 era characterized as building a 'country of geniuses in a datacenter' — AI enables 'biological freedom', giving humanity insights to cure complex diseases (cancer, Alzheimer's) and rapidly extend healthy human lifespan over the coming decade; same...

2026 era characterized as building a 'country of geniuses in a datacenter' — AI enables 'biological freedom', giving humanity insights to cure complex diseases (cancer, Alzheimer's) and rapidly extend healthy human lifespan over the coming decade; same algorithmic architectures displacing software engineers will brute-force molecular biology. | First AI-designed molecule cancer cure approval

Key catalyst: First AI-designed molecule cancer cure approval

Watch events: First AI-designed cancer drug FDA approval

Amodei 'Machines of Loving Grace' essay formalizes framing; AI-drug-discovery startups (Recursion, Xaira, Iambic) scaling; Alzheimer's cure remains elusive despite AI acceleration.

No probability history yet. The first evidence will arrive via /api/intake or the daily milestone sweep / weekly LBP run.

No propagation data yet. Run inference/.venv/bin/python scripts/ops/run_loopy_belief_propagation.py on the droplet, or wait for the Sunday 02:00 UTC weekly cron.

Beneficiaries (20)

{
  "nia": false,
  "mode": "FORECAST",
  "role": "Cited-CEO",
  "context": "Third Amodei biotech entry (CMQ_006 cancer/Alzheimer cure 5-10yr, AUT_009 Powerful AI). Specific 'country of geniuses' coinage + 'biological freedom' framing.",
  "to_year": 2036,
  "conv_cues": "CEO FIRST_PERSON; coined framings",
  "direction": "HAPPEN",
  "from_year": 2026,
  "timeframe": "2026-2036",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "First Anthropic / OpenAI / DeepMind 'genius-level' demonstration: AI completes a task accepted as 'multi-week PhD-level research' in <1 day",
      "source": "Dario Amodei 'powerful AI by 2026-2027'; METR HCAST trends",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.55,
      "source_url": "https://www.darioamodei.com/essay/machines-of-loving-grace",
      "expected_date": "2027-06-30",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2028-06-30",
        "from": "2026-06-30"
      },
      "measurement_criterion": "Public benchmark (RE-Bench, MLE-Bench, or successor) shows frontier agent matching or beating expert human performance on multi-week research projects with <24h wall-clock time"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -7,
      "source_id": null,
      "expected_date": "2027-12-27",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "100GW+ frontier AI training campus operational",
      "source": "OpenAI Stargate $500B; Sam Altman 7T compute aspiration",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -6,
      "source_id": null,
      "confidence": 0.35,
      "expected_date": "2028-12-29",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-06-30",
        "from": "2027-06-30"
      },
      "measurement_criterion": "Stargate, Anthropic-Amazon Rainier, Microsoft, or peer announces 100GW-class campus with first multi-site training run completed"
    },
    {
      "kind": "llm_pre_event",
      "label": "AI-driven cancer breakthrough: novel mechanism or candidate published in Nature/NEJM/Cell",
      "source": "Isomorphic Labs oncology pipeline; Recursion/Bayer collaboration",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2028-12-31",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-12-31",
        "from": "2027-01-01"
      },
      "measurement_criterion": "Peer-reviewed publication of novel cancer mechanism, target, or therapeutic candidate primarily discovered by AI (Recursion, Isomorphic, Insilico, OpenAI o-series, or DeepMind successor) with reproducibility validated by independent labs"
    },
    {
      "kind": "llm_pre_event",
      "label": "Healthy human lifespan-extension intervention enters Phase II/III at scale",
      "source": "TAME Trial; Altos Labs; Calico LSP",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -4,
      "source_id": null,
      "confidence": 0.4,
      "expected_date": "2029-03-31",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2030-12-31",
        "from": "2027-06-30"
      },
      "measurement_criterion": "Phase II/III trial with >=1000 participants targeting biological-age reduction or healthspan extension as primary endpoint, sponsored by major pharma or Altos/Calico/peer; registered on ClinicalTrials.gov"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -3,
      "source_id": null,
      "expected_date": "2029-12-21",
      "observed_date": null
    },
    {
      "kind": "llm_post_event",
      "label":
... (truncated)